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Background: To determine the role played by vascular endothelial growth factor (VEGF) in polypoidal choroidal
vasculopathy (PCV) based on an interventional immunology theory.
Methods: Eyes with PCV were divided in a masked fashion into those with choroidal hyperpermeability (HP group)
and those with normal choroidal permeability (NP group) based on the indocyanine green angiograms. The inter-rater
agreement rate was evaluated using Fleiss’ kappa. Patients were treated by intravitreal ranibizumab (IVB). The central
choroidal thickness and central foveal thickness (CFT) at the baseline and 7 days after the treatment were measured by
optical coherence tomography.
Results: Among the 57 consecutive eyes diagnosed with PCV, 42 eyes of 42 patients met the inclusion criteria
(21 eyes/HP group vs 21 eyes /NP group). Central choroidal thickness in HP group was significantly thicker than that in
the NP group (P < .001, Mann–Whitney U test). The inter-rater agreement was high with a Fleiss’ kappa = 0.95, P < .0001.
The percentage reduction in the CFT in HP group (14.0%) was significantly less than that in NP group (20.4%; P = .013,
Mann–Whitney U test).
Conclusions: Eyes with PCV that are associated with choroidal hyper-permeability may not be strongly associated with
VEGF-related pathology, and may not respond favorably to anti-VEGF monotherapy.
Keywords: AMD, Drug, Enhanced depth imaging optical coherence tomography interventional immunology,
RanibizumabBackground
Polypoidal choroidal vasculopathy (PCV) is character-
ized by the presence of polyp-like lesions at the termi-
nals of a branching network of choroidal vessels and is
the more common type of exudative age-related macular
degeneration (AMD) in the Asian population [1,2]. Al-
though typical AMD and PCV are placed under the
same category of exudative AMD [3], some cases of
PCV have been reported to have a unique characteristic
of choroidal vascular hyperpermeability [4,5]. This may
indicate that this subgroup of PCV eyes with hyper-
permeability has properties that are more like those of* Correspondence: tsakamot@m3.kufm.kagoshima-u.ac.jp
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reproduction in any medium, provided the oreyes with central serous chorioretinopathy (CSC) which
also have vascular hyperpermeability.
The major treatments for a subfoveal PCV are photo-
dynamic therapy (PDT), intravitreal ranibizumab (IVR),
an anti-vascular endothelial growth factor (VEGF) anti-
body, or a combination of PDT and anti-VEGF therapy
[1,6-10]. The efficacy of IVR for PCV has been reported
to be less than that for typical AMD [6,11,12]. Thus, a
more effective and safer treatment is needed [12].
The rationale for IVR is that it targets and deactivates
VEGF, and its effectiveness has been generally deter-
mined by a reduction in retinal thickness. Thus, a meas-
urement of choroidal thickness may provide clues that
might help determining not only the effectiveness of IVR
but also help determine the pathogenesis of PCV
[13,14]. For example, it was reported that the choroidall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hyperpermeability, and gene polymorphisms [15-17].
Biologic agents can facilitate the dissection of the role
played by the target of the agent in the disease process.
Consequently, disease-focused investigations can acquire
a level of experimental sophistication that has been the
exclusive domain of animal studies [18]. Not only can
this form of experimental medicine add substantially to
our understanding of the pathogenesis of disease, but it
can also aide in the development of new therapies. This
concept has been called interventional immunology
which is now a fast growing field in experimental medi-
cine [19]. Similarly, treatments based on antibody-drug
methodology, e.g., IVR, can produce a so-called knock-
out (KO) condition in human eyes [20]. This would then
provide direct evidence on the effects of VEGF on the
disease process.
Thus, the purpose of this study was to determine the
responsiveness of eyes with PCV to IVR. To accomplish
this, we treated eyes with PCV and choroidal hyper-
permeability and eyes with normal choroidal permeabil-
ity with IVR. To assess the effectiveness of IVR, we used
a new method of studying the choroid by spectral-
domain optical coherence tomography (OCT) called en-
hanced depth imaging OCT (EDI-OCT).
Methods
The procedures used in this study were approval by the Insti-
tutional Review Board of the Kagoshima University Graduate
School of Medical and Dental Sciences, Kagoshima, Japan.
The procedures conformed to the tenets of the 1989
Declaration of Helsinki.
We reviewed the medical records of patients diagnosed
with PCV who were examined between September 2010
and December, 2011. The clinical diagnosis of PCV was
based on the presence of polypoidal choroidal vessels in the
ICGA images. All patients underwent a comprehensive
ophthalmological examination including measurements
of the best-corrected visual acuity (BCVA), intraocular
pressure measurements, slit-lamp biomicroscopy, dilated
funduscopic examination, and fundus photography. Fluores-
cein angiography (FA), indocyanine green angiography
(ICGA), and EDI-OCT were performed with the Heidelberg
Spectralis® OCT and HRA instruments (Heidelberg
Engineering, Heidelberg, Germany). The clinical diagno-
sis of PCV was based on the presence of polypoidal chor-
oidal vessels in the ICGA images. The inclusion criteria
were: presence of subfoveal serous retinal detachment or
serous pigment epithelial detachment (PED) or both at
the fovea; absence of hemorrhage and fibrin at the fovea;
absence of an obvious fibrovascular membrane at the
fovea; no previous PDT or IVR; and active leakage on FA
caused by the PCV including choroidal vascular
hyperpermeability and not from other diseases.The patients were divided into a hyperpermeability
group (HP group) and a normal choroidal permeability
group (NP group) based on the ICGA finding of chor-
oidal hyperfluorescence in the midphase of ICGA about
10 minutes after ICG injection. The classification was
made by 3 masked graders independently (NA, SS, HO).
The eyes with choroidal hyperpermeability, i.e., chor-
oidal vessels with leakage of the ICG dye, were classified
according to an earlier study and were placed in the HP
group [4]. Three graders classified each case independ-
ently without any information about the eye including
the choroidal thickness. When there was a disagreement,
the classification supported by two graders was chosen
as the final classification. All cases were classifiable. Be-
cause the classification was subjective, the inter-grader
agreement rate was evaluated by the Fleiss’s kappa meas-
ure to assess the reliability of the agreements.
The central choroidal thickness and the central foveal
thickness (CFT) at the baseline and 7 days after the IVR
were measured in the EDI-OCT images with a follow-up
program as we have described in detail [21]. Following
each examination, the best image was projected onto
a computer screen and evaluated by 2 independent
masked graders (NA and MS). Measurements of the
choroidal thickness (rating) was done in a masked fash-
ion by these raters with no information of the eyes. For
inter-rater comparisons, each image was measured by
two raters with no information of eyes or the results by
the other rater. These two values were used for the ana-
lysis. The average of the results by two raters was used
for the analysis of choroidal thickness. All of the images
were obtained using the eye-tracking system. The OCT
Star (enhanced depth imaging) protocol with 768 A
scan/B scan and averaged 100 scans was used. The cen-
tral choroidal thickness was measured from the border
of Bruch’s membrane to the inner border of the sclera.
The CFT was measured between the inner border of the
neurosensory retina and Bruch’s membrane including
any PED. The percentage reduction in the CFT was cal-
culated by the following formula.
Percentage reduction rate (%) = 100 × (1-[post-IVR
CFT/baseline CFT]).
The best-corrected visual acuity (BCVA) was mea-
sured with a Japanese standard decimal visual chart at
the baseline and 7 days after the IVR. The decimal acuity
was converted to the logarithm of the minimal angle of
resolution (logMAR) units for the statistical analyses.
The age, sex, treated eye, abnormal findings, e.g., RPE
atrophy, drusen, and PED in the contralateral eye, lens
status, and refractive error were also obtained from the
medical charts.
All statistical analyses were performed with the statis-
tical programming language R (ver. 2.11.1, The R Foun-
dation for Statistical Computing, Vienna, Austria). The
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kappa coefficient. The Mann–Whitney U test and Chi-
square test were used to determine the significance of dif-
ferences of 2 groups. The inter-rater correlation coefficient
using a two-way mixed effects model for measurements of
absolute agreement were computed. Multivariate regres-
sion (stepwise) analysis was performed on age, sex, per-
meability, CCT, laterality, baseline CMT, lens status,
refraction, and baseline logMAR BCVA. A P value < .05
was considered statistically significant. A Fleiss’ kappa
value of 0.01 to 0.20 was considered to be a slight agree-
ment, 0.21 to 0.40 a fair agreement, 0.41 to 0.60 as moder-
ate agreement, 0.61 to 0.80 as substantial agreement, and
0.81 to 1.0 as very good agreement as reported [22]. A
kappa value <0 was considered to be no agreement.
Results
Fifty-seven eyes without previous treatment were diag-
nosed with PCV, and 42 of these eyes of 42 patients met
the inclusion criteria. Among the 15 excluded eyes, ten
eyes were excluded because of the presence of hemor-
rhage or fibrin at the fovea, 3 eyes because of the pres-
ence of a fibrovascular membrane, and 2 eyes because of
a lack of clear OCT images.
In the classification of the 42 eyes, 38 eyes were unani-
mously agreed to by the three raters and 4 were not
unanimous. For the agreement between raters, intraclass
correlation coefficient expressed as Fleiss’ kappa was
0.95 (P < .0001, 95% confidential interval 0.92 – 0.97),
which is an almost perfect agreement [22].
In the end, 21 eyes were placed in the HP group and
21 in the NP group. The baseline demographics of each
group are summarized in Table 1. The fundus photo-
graphs and the ICGA and OCT findings of a representa-
tive case from the NP group are shown in Figure 1, and
those of a representative case from the HP group are
shown in Figure 2.
The mean age of the HP group was 64.5 ± 6.8 years, and
16 (76.2 %) of them were men. The mean age of the NP
group was significantly older at 72.4 ± 9.4 years (P = .008),






Gender (M/F) 16 / 5 13 / 8 0.317†
Age (y.o.) 64.5 ± 6.8 72.4 ± 9.4 0.008‡*
Treated eye (R/L) 9 / 12 8 / 13 0.753†
Contralateral eye involvement (+/−) 3 / 13 7 / 14 0.277†
Lens status (IOL eye) 2 0 0.147†
Refraction (D) 0.14 ± 1.82 0.55 ± 2.10 0.458‡
†Chi-square test. ‡Mann–Whitney U test. *Significant value.
D Diopter, F Female, HP Hyperpermeability, IOL Intraocular lens, M Male, NP
Normal permeability.incidence of choroidal vascular hyperpermeability between
men and women was not significant. In addition, the inci-
dence of the contralateral eye involvement, laterality of
the treated eye, lens status, and refractive at the baseline
error were not significantly different between the HP and
the NP groups. The BCVA at the baseline and at 7 days
after IVR were not significantly different between the two
groups, and the IVR did not improve the BCVA for at
least 7 days after the treatment in both groups.
The inter-rater agreement of the choroidal thickness
was very high with a coefficient of variance 0.932. The
intraclass correlation coefficient had a 95% confidence
interval of 0.887 to 0.964.
The mean central choroidal thickness at the baseline
was significantly thicker in the HP group than in the NP
group (378.6 ± 92.5 μm vs 192.5 ± 58.1 μm; P < .001). A
significant reduction of the mean CFT between baseline
and post-IVR was found in both groups. In addition, the
percentage reduction of the CFT in the HP group was
significantly less than in the NP group (14.0 ± 7.5% vs
20.4 ± 8.7%; P = .013; Table 2). Additionally, multivariate
regression (stepwise) analysis was performed on age, sex,
permeability, CCT, laterality, baseline CMT, lens status,
refraction, and baseline logMAR BCVA. This allowed us
to obtain the variables for the regression equations in-
cluding permeability (HP or NP) and laterality. As a re-
sult, R = 0.478 with a P-value of 0.009 for permeability
and 0.042 for laterality. Thus, the FA permeability of
choroid was still significant for the reduction of CFT.
Discussion
Our ICGA results showed that the choroid of about
one-half of the eyes with PCV were hyperpermeable to
indocyanine green. In addition, the choroid of these eyes
was significantly thicker than that of eyes with normal
permeability which is in agreement with earlier reports
[15,16]. This is important because these eyes responded
less well to IVR, viz., the percentage reduction in the
CFT after IVR in these eyes was significantly less than
that in eyes with normal permeability. This would sug-
gest that the CFT in these eyes was less influenced by an
up-regulation of VEGF than the eyes with normal
permeability.
Choroidal vascular hyperpermeability is also present in
eyes with CSC, and the hyperpermeability of choroid has
been suggested to be the pathophysiological basis of
CSC [23-25]. Hyperpermeable choroidal vessels increase
the tissue hydrostatic pressure, which overpowers the
barrier functions of the RPE leading to serous retinal de-
tachments [26]. There are various factors that cause the
hyperpermeability of the choroid in CSC such as stasis,
ischemia, inflammation, and other related factors [27].
At present, PDT is regarded to be the standard treat-
ment for CSC [27]. Although the real mechanism of
Figure 1 Fundus photograph, indocyanine green angiogram, and EDI-OCT images of an eye with normal choroidal permeability (NP
group). An orange-colored polypoidal lesion can be seen adjacent to the foveal area (top left). Indocyanine green angiogram shows a polypoidal
vascular lesions (top right). Choroidal hyperpermeability is not apparent throughout the examination (top right). EDI-OCT shows an elevation of
the RPE layer and serous retinal detachment (middle). Seven days after intravitreal ranibizumab (IVR), the serous retinal detachment is reduced
(bottom).
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mined, it is assumed that PDT induces choroidal vascu-
lar remodeling with thinning of the choroid [28]. This
effect was assumed to also occur in eyes with PCV by
the frequent disappearance of the polypoidal lesions
after PDT treatment [7].
On the other hand, anti-VEGF agents are not consid-
ered first-line treatments for CSC. Several small trials
have yielded suggestive results, although their effective-
ness has not been confirmed. Bae et al. showed in a
small randomized trials that half-fluence PDT may besuperior to anti-VEGF agent as a treatment for CSC
[29]. Anti-VEGF agents are highly effective in reducing
subretinal fluid, reducing extravasation from retinal ves-
sels, and neovascularization, but they may not be suffi-
cient to reduce the hyperpermeability of the choroid in
eyes with CSC and PCV. The similarities between the
PCV eyes with hyperpermeability and CSC eyes suggest
that they may share features relating to their pathogen-
esis and pathophysiology [6,10,11,27].
Lim et al. reported that the responsiveness to beva-
cizumab as shown by the resolution of the subretinal fluid
Figure 2 Fundus photograph, indocyanine green angiogram, and EDI-OCT image of an eye with PCV with choroidal hyperpermeability
(HP group). An orange-colored polypoidal lesion surrounded by hard exudates can be seen between the optic disc and macular area (top left).
Indocyanine green angiogram shows several vascular polypoidal lesions. Choroidal hyperpermeability (arrow heads) can be seen (top right).
EDI-OCT image shows an elevation of the RPE layer and thick choroid. Serous retinal detachment is also seen (middle). Seven days after IVR, the
elevated RPE layer, serous retinal detachment, and thickened choroid did not change significantly (bottom).
Table 2 Comparison of choroidal/foveal thickness and visual acuity between two groups
HP group (n = 21) NP group (n = 21) P value†
Central choroidal thickness (μm) 378.6 ± 92.5 192.5 ± 58.1 <.001*
Baseline CFT (μm) 424 ± 147 461 ± 174 0.554
Post CFT (μm) 363 ± 131 366 ± 140 0.821
Reduction rate of CFT (%) 14.0 ± 7.5 20.4 ± 8.7 0.013*
Baseline VA 0.281 ± 0.269 0.365 ± 0.377 0.725
Post VA 0.274 ± 0.250 0.368 ± 0.392 0.715
†Mann–Whitney U test. *Significant value. CFT Central foveal thickness, HP Hyperpermeability, NP Normal permeability, VA Visual acuity.
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hyperpermeability. Their results are just the opposite of
our results [23]. However, Koizumi et al. recently reported
that the responsiveness to ranibizumab, expressed as reso-
lution of retinal fluid in eyes with PCV, was worse in eyes
with than without hyperpermeability which is consistent
with our results [30]. Lim et al. studied eyes with CSC and
not with PCV. Although CSC and PCV have certain simi-
larities, they are not the same disease. Additionally, the def-
inition of hyperpermeability in CSC may not be the same
as that of PCV. These factors might explain the different
response patterns to the treatment between the reports.
In this past decade, new treatments have been intro-
duced for exudative AMD [1,6]. PDT alone or IVR alone
or a combination of the two have been used to treat AMD
with sub- or juxta-foveal lesions but the outcomes of these
therapies have not been consistent. PDT was not as effect-
ive for eyes with typical AMD but relatively better for eyes
with PCV [6,7]. In contrast, anti-VEGF therapy was more
effective for eyes with typical AMD, but its effectiveness
on eyes with PCV was clearly inferior to that on eyes with
typical AMD [6,11]. However, it has not been determined
whether the type of treatment for cases of typical AMD
should be different from that of cases of PCV.
Our results indicated that the choroidal thickness might
serve as an indicator of the responsiveness of an eye to
anti-VEGF treatment. For example, it is known that the
choroid is very thin in eyes with pathological myopia [31].
Our findings suggest that IVR would be effective in redu-
cing the CFT in these eyes. This has been confirmed by a
study that showed that anti-VEGF treatment for choroidal
neovascularizations secondary to pathological myopia was
effective [32]. Therefore, the association between chor-
oidal thickness and the efficacy of IVR should be deter-
mined for other types of exudative AMDs.
There have been recent reports on the results of com-
bined PDT and anti-VEGF antibodies to treat PCV. Lai
et al. reported that IVR resulted in a stabilization of vi-
sion in patients with symptomatic PCV. However, com-
bined IVR and PDT appeared to be more effective in
causing a complete regression of the polypoidal lesions
in ICGA compared with IVR monotherapy [33]. Others
have shown the comparatively good results for main-
taining the visual acuity [34,35]. Because there is no
large scaled analysis of anti-VEGF monotherapy and
combination therapy, the results are not conclusive.
Considering our cases with PCV that are non-responsive
to IVR, it might be meaningful to select specific cases
requiring PDT rather than IVR (with or without PDT).
The present finding would be helpful for that.
More importantly, there is another consequence of
our findings. Treatments based on antibody-drug tech-
nology including IVR could produce a so-called knock-
out (KO) condition in human eyes. So far, this conditionhas been accomplished only in animals because of ethical
reason, however the results from animal studies do not
necessarily reflect those of human disease. The present
method and interpretation, called interventional immun-
ology, might be suitable for ocular diseases because the
eye is a relatively closed system and is less affected by the
systemic circulation [18,19]. Although molecules injected
into the vitreous can appear in systemic circulation, its
effect is less than after an intravenous injection as is
performed in cancer therapy.
Currently, PCV is classified as being a type of AMD,
but recent genetic analysis and angiographic studies of
Japanese populations showed that there are some sub-
types of PCV [36-38]. Our findings showed the role of
VEGF in the disease process of PCV, and these eyes
may be a sublclass of PCV eyes that are not related to
VEGF pathology.
From the early days of PCV study, it was asked whether
PCV originated from abnormal choroidal vessels or was a
variant of type 1 CNV [4-6]. This issue might be related to
the responsiveness to IVR. Further studies are needed. To
answer this question, further studies with more advanced
method such as simultaneous ICGA and eye-tracked SD-
OCT would be helpful in obtaining an answer [39].
The limitations of this study are the relatively small
number of patients studied and the short follow-up
period. Because we limited our patients to those that
had neither apparent hemorrhage nor fibrin but had
pure serous exudation at the fovea, the responsiveness
to IVR could be detected clearly even 7 days after the
IVR. In addition, we showed the short term effects of
anti-VEGF drug. Because VEGF is not only an angio-
genic factor but also a pluripotent inflammatory factor,
the long term in vivo results can be affected by various
factors other than VEGF [40]. Thus, the short term re-
sults would be more meaningful for evaluating the direct
effect of VEGF on PCV pathology. However, this does
not necessarily mean that the long term results might
not be the same. Even though, the classification was
done in a masked fashion and high inter-rater agreement
was obtained as confirmed by a Fleiss’s kappa of 0.95,
this was not a perfectly objective system and this
method is not equally applicable to every clinical setting.
In addition, this was not a prospective randomized study
but a retrospective study. As was described in the
Results section, eyes with hazy media or poor OCT
images were not included in this study. Thus, there is a
potential selection bias in this study. These issues should
be remembered when interpreting our results.
Conclusions
In conclusion, some of the eyes with PCV had choroidal
hyperpermeability, and these eyes were less responsive to
IVR. This would suggest that the choroidal permeability in
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ology. For these eyes, combination therapy might be more
suitable than IVR monotherapy. Evaluation of the chor-
oidal thickness may be a way of predicting the responsive-
ness of eyes with PCV to IVR. Future studies need to be
performed to determine whether this relationship is
present in other types of exudative AMDs.
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